We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

ThromboGenics and BioInvent Report Positive Phase I Results for Anti-PlGF Cancer Therapeutic TB-403

News   Jun 04, 2008

 
ThromboGenics and BioInvent Report Positive Phase I Results for Anti-PlGF Cancer Therapeutic TB-403
 
 
Advertisement
 

RELATED ARTICLES

Team Synthesizes Safer Nonaddictive Analgesics

News

A team has discovered a new class of drugs, capable of relieving pain and reducing fever without the danger of addiction or damage to the liver or kidneys.

READ MORE

Compounds Target Key Enzyme Halting SARS-CoV-2 Replication

News

Researchers have identified several existing compounds that block replication of the COVID-19 virus (SARS-CoV-2) within human cells grown in the laboratory.

READ MORE

Hydroxychloroquine and Lopinavir/Ritonavir Treatment Arms for COVID-19 Discontinued

News

The World Health Organization (WHO) has accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue hydroxychloroquine and lopinavir/ritonavir study arms.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE